deltatrials
Terminated PHASE3 INTERVENTIONAL 4-arm NCT04985136

A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)

A Randomized, Open-Label, Controlled, International Multi-Center Phase III Clinical Study of Camrelizumab Combined With Rivoceranib (Apatinib) Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Hepatocellular Carcinoma (HCC) Who Have Been Treated With Immune Checkpoint Inhibitors (ICIs)

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Conditions Advanced Hepatocellular Carcinoma (HCC)
Interventions Regorafenib Rivoceranib Sorafenib camrelizumab；Rivoceranib
Updated 6 times since 2021 Last updated: Aug 29, 2022 Started: Sep 26, 2021 Primary completion: Dec 29, 2021 Completion: Dec 29, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor R \& D Strategy Adjustment

Other terminated trials from Jiangsu HengRui Medicine Co., Ltd.

More terminations from Jiangsu HengRui Medicine Co., Ltd.

Other Advanced Hepatocellular Carcinoma (HCC) trials with similar outcome

Browse all Advanced Hepatocellular Carcinoma (HCC) trials

This PHASE3 trial investigates Advanced Hepatocellular Carcinoma (HCC) and is currently terminated or withdrawn. Jiangsu HengRui Medicine Co., Ltd. leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshotNot Yet Recruiting~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshotRecruiting~Nov 2021 – ~Sep 2022 · 10 months · monthly snapshotEnrolling By Invitation~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  3. Sep 2022 — Jul 2024 [monthly]

    Terminated PHASE3

    Status: Enrolling By Invitation → Terminated

  4. Nov 2021 — Sep 2022 [monthly]

    Enrolling By Invitation PHASE3

    Status: Recruiting → Enrolling By Invitation

  5. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

  1. Sep 2021 — Oct 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Jiangsu HengRui Medicine Co., Ltd.
Data source: Jiangsu HengRui Medicine Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations